论文部分内容阅读
目的探讨艾迪注射液联合培美曲塞和顺铂治疗晚期肺腺癌的疗效。方法选取88例晚期肺腺癌患者,按随机数字表法均分为观察组(44例,艾迪注射液+培美曲塞+顺铂治疗)和对照组(44例,培美曲塞+顺铂治疗),观察两组患者临床疗效及不良反应。结果观察组患者治疗有效率为72.7%,对照组为68.2%,差异无统计学意义(P>0.05)。观察组患者Karnofsky体力状况(KPS)评分显效18例(40.9%),显著高于对照组(11例,25.0%;P<0.05)。观察组患者体质量增加21例(47.7%),显著高于对照组(12例,27.3%;P<0.05)。观察组患者血小板减少、血红蛋白减少、中性粒细胞减少、胃肠道反应发生率显著低于对照组(P<0.05)。结论晚期肺腺癌患者采用培美曲塞和顺铂化疗联合艾迪注射液治疗,不仅能改善患者对化疗药物不良反应的耐受性,还能提高患者生存质量,值得推广使用。
Objective To investigate the curative effect of Aidi injection combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma. Methods Eighty-eight patients with advanced lung adenocarcinoma were enrolled and randomly divided into observation group (44 cases, Aidi Injection + pemetrexed + cisplatin) and control group (44 cases, pemetrexed + Cisplatin treatment), observe the clinical efficacy and adverse reactions in both groups. Results The effective rate of treatment was 72.7% in the observation group and 68.2% in the control group, with no significant difference (P> 0.05). The scores of Karnofsky physical condition (KPS) in observation group were markedly improved in 18 cases (40.9%), which were significantly higher than those in control group (11 cases, 25.0%, P <0.05). In the observation group, the body mass increased in 21 cases (47.7%), which was significantly higher than that in the control group (12 cases, 27.3%; P <0.05). The incidence of thrombocytopenia, hemoglobin decrease, neutropenia and gastrointestinal reaction in observation group was significantly lower than that in control group (P <0.05). Conclusions The use of pemetrexed and cisplatin combined with Aidi injection in patients with advanced lung adenocarcinoma can not only improve patients’ tolerance to adverse reactions of chemotherapy drugs, but also improve their quality of life, which is worthy of promotion.